Attenuex Technologies, Inc.

Solace Therapeutics, Inc.

Galt Laboratories, Inc.

Cascade Ophthalmics, Inc.

Other

Galt Incorporated

Galt Laboraties, Inc.

Sheila K Wallin

William L Pintauro

Kevin Gerald Connors

Hung H Cao

John T Kilcoyne

Khoi M Nguyen

Matthew Thomas Yurek

Rodney A Brenneman

Mario Maciel

David G Matsuura

Walter Dean Gillespie

Edward T Bullister

Peter P Huo

Mathew T Yurek

Matthew T Yurek

Edward Bullister

Walter D Gillespie

An inflated implant, such as an attenuation device, previously implanted in a urinary bladder can later be removed according to a number of different methods. Preferably, removal is accomplished transurethrally. In one embodiment, removal is accomplished by reducing the inflated implant from an enlarged profile to a reduced profile so that it may be withdrawn transurethrally by a removal system. The removal system can be configured differently depending upon whether reduction from the enlarged profile to the reduced profile is accomplished by deflation, compression, and/or other ways.

Attenuation device for use in an anatomical structure

An inflated implant, such as an attenuation device, previously implanted in a urinary bladder can later be removed according to a number of different methods. Preferably, removal is accomplished transurethrally. Removal can be accomplished by reducing the inflated implant from an enlarged profile to a reduced profile so that it may be withdrawn transurethrally by a removal system. The removal system can be configured differently depending upon whether reduction from the enlarged profile to the reduced profile is accomplished by deflation, compression, and/or other ways.

Method of removing an inflated implant from a bladder

Measurement of a patient's leak point pressure in the bladder can be taken by a processor in communication with a pressure catheter in the bladder. When leakage occurs pressure data points can be recorded. In some embodiments, the peak pressure can be determined based on pressure data points measured during a set time just before receiving a clinician input indicative that leakage has occurred.

Method and system for measuring leak point pressure in a bladder

Disclosed herein are methods of treating a patient with benign hypertrophy of the prostate, comprising providing a compressible attenuation device that is moveable from a first, introduction configuration to a second, implanted configuration and attenuating a pressure change within the bladder by reversibly changing the volume of the attenuation device in response to the pressure change. In one embodiment, the attenuation device is advanced percutaneously into the bladder. In another embodiment, the attenuation device is positioned within the bladder to inhibit a decrease in compliance of the bladder wall as a consequence of the benign hypertrophy of the prostate.

Method of treating benign hypertrophy of the prostate

Disclosed herein is an attenuation device, comprising a flexible housing and a high vapor pressure media having a permeability of less than 1 ml/day at body temperature through the outer wall of the flexible housing. In one embodiment, the high vapor pressure media comprises perfluorooctylbromide. In another embodiment, the high vapor pressure media comprises perfluorohexane. In yet another embodiment, the high vapor pressure media comprises perfluorodecalin. Also disclosed herein is a method of treating a patient, comprising providing a compressible attenuation device and introducing within the attenuation device at least one high vapor pressure media.

Attenuation device for treating glaucoma

Disclosed herein is an attenuation device comprising a flexible housing and a medium capable of transformation to inflate the housing from the first configuration to the second configuration. Also disclose herein are methods of treating a patient, comprising: providing a self-inflating expandable attenuation device, containing a medium which is transformable from a first, reduced volume to a second, expanded volume; positioning the attenuation device within the patient at a treatment site; and transforming the medium from the first volume to the second volume. In one embodiment, a self-inflating expandable attenuation device is used to treat glaucoma.

Implantable self-inflating attenuation device and method for treating ocular pressure spikes

Disclosed herein are methods of treating a patient with benign hypertrophy of the prostate, comprising providing a compressible attenuation device that is moveable from a first, introduction configuration to a second, implanted configuration and attenuating a pressure change within the bladder by reversibly changing the volume of the attenuation device in response to the pressure change. In one embodiment, the attenuation device is advanced transurethrally into the bladder. In another embodiment, the attenuation device is positioned within the bladder to inhibit a decrease in compliance of the bladder wall as a consequence of the benign hypertrophy of the prostate.

Disclosed herein is an attenuation device, comprising a flexible housing and a high vapor pressure media having a vapor pressure approximately equal to the intravesical pressure of the bladder and a permeability of less than 1 ml/day at body temperature through the outer wall of the flexible housing. In one embodiment, the high vapor pressure media comprises perfluorooctylbromide. In another embodiment, the high vapor pressure media comprises perfluorohexane. In yet another embodiment, the high vapor pressure media comprises perfluorodecalin. Also disclosed herein is a method of treating a patient, comprising providing a compressible attenuation device and introducing within the attenuation device at least one high vapor pressure media.

High vapor pressure attenuation device

Disclosed herein are methods of treating a patient, comprising providing a compressible attenuation device that is moveable from a first, introduction configuration to a second, implanted configuration. The attenuation device is introduced into a treatment site. In one embodiment, the treatment site is the bladder. In another embodiment, the treatment site is the abdominal cavity. The volume of the attenuation devices changes in response to pressure changes in the treatment site and attenuates pressure changes in the bladder.

Treatment of patients with a compressible attenuation device

Disclosed herein is an attenuation device comprising a flexible housing and a medium capable of transformation to inflate the housing from the first configuration to the second configuration. Also disclose herein are methods of treating a patient, comprising: providing a self-inflating expandable attenuation device, containing a medium which is transformable from a first, reduced volume to a second, expanded volume; positioning the attenuation device within the patient at a treatment site; and transforming the medium from the first volume to the second volume. In one embodiment, a self-inflating expandable attenuation device is used to treat urinary tract dysfunction. In another embodiment, a self-inflating expandable attenuation device is used to treat benign hypertrophy of the prostate.

Implantable self-inflating attenuation device

Disclosed herein are devices for treating symptoms of a urinary tract dysfunction having an expanded volume within the range of from about 1 cc to about 400 cc. In one embodiment, the device comprises a valve having a first membrane and a second membrane with a flow passage therebetween for filling the attenuation device. In another embodiment, the device comprises a valve for permitting the filling of the attenuation device through a filling device.

Implantable valved pressure attenuation device

Disclosed are pressure attenuators, for attenuating pressure changes in an anatomical structure. The attenuators are movable from a first, introduction configuration to a second, implanted configuration. When in the second, implanted configuration, the attenuator attenuates pressure spikes within the body by reversibly reducing in volume in response to the pressure spike. In one application, the attenuator is utilized to treat urinary tract dysfunctions. Deployment devices, retrieval devices, and methods are also disclosed.

Devices and methods for attenuation of pressure waves in the body

Disclosed herein are bioadhesive medical devices formed in whole or in part of a cohesive bioadhesive copolymer of a carboxyl functional monomer and a hydrophobic functional monomer.

Bioadhesive medical devices

A prosthetic device for controlling urinary continence is disclosed. The device has an opening pressure that varies in response to changes in physiologic parameters. The device can be controlled by the patient voluntarily without manual intervention. An introducer for transurethrally introducing the device is also disclosed. In addition, a nonsurgical or minimally invasive method of positioning the device for maintaining urinary continence is disclosed.

Growing community of inventors

Carlsbad, CA, United States of America

Sheila K Wallin